Tiffany Baumann

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Catherine J. Mummery, Anne Börjesson‐Hanson, D. Blackburn et al. · Nature Medicine · 2023 · 318 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A double‐blind, randomized, controlled trial

C. Warren Olanow, Raymond T. Bartus, Tiffany Baumann et al. · Annals of Neurology · 2015 · 282 citations

Medicine, Neurology, Neuroscience +17

A phase1 study of stereotactic gene delivery of AAV2‐NGF for Alzheimer's disease

Michael S. Rafii, Tiffany Baumann, Roy A.E. Bakay et al. · Alzheimer s & Dementia · 2014 · 223 citations · Full text

Pharmacy, Neurology, Neuroscience +17

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

Raymond T. Bartus, Tiffany Baumann, João Siffert et al. · Neurology · 2013 · 213 citations · Full text

Medicine, Neurology, Neuroscience +16

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

Raymond T. Bartus, Jeffrey H. Kordower, Eugene M. Johnson et al. · Neurobiology of Disease · 2015 · 81 citations · Full text

Life Sciences, Neurology, Neuroscience +12